AbbVie Details Senior Notes in Latest 8-K Filing

TL;DR

**AbbVie just updated its debt structure, detailing various senior notes with different maturities and interest rates.**

AI Summary

AbbVie Inc. filed an 8-K on February 26, 2024, reporting on "Other Events" and "Financial Statements and Exhibits" as of February 22, 2024. The filing details various senior notes with different interest rates and maturity dates, including 1.375% due 2024, 1.250% due 2024, 0.750% due 2027, 2.125% due 2028, 2.625% due 2028, 2.125% due 2029, and 1.250% due 2031. This indicates ongoing financial activities related to its debt structure.

Why It Matters

This filing provides transparency into AbbVie's current debt obligations and financing activities, which can influence its financial health and future investment capacity.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of existing debt instruments and does not indicate new, significant risks.

Key Numbers

• 1.375% — Senior Notes Interest Rate (Due 2024)
• 1.250% — Senior Notes Interest Rate (Due 2024 and 2031)
• 0.750% — Senior Notes Interest Rate (Due 2027)
• 2.125% — Senior Notes Interest Rate (Due 2028 and 2029)
• 2.625% — Senior Notes Interest Rate (Due 2028)

Key Players & Entities

• AbbVie Inc. (company) — Filing company
• 1.375% (dollar_amount) — Interest rate on senior notes due 2024
• 1.250% (dollar_amount) — Interest rate on senior notes due 2024 and 2031
• 0.750% (dollar_amount) — Interest rate on senior notes due 2027
• 2.125% (dollar_amount) — Interest rate on senior notes due 2028 and 2029
• 2.625% (dollar_amount) — Interest rate on senior notes due 2028
• February 22, 2024 (date) — Conformed period of report
• February 26, 2024 (date) — Filed as of date

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 Par Value ABBV New York Stock Excha
• $15.0 billion — d to issue and sell to the Underwriters $15.0 billion aggregate principal amount of its senio
• $2,250,000,000 — ount of its senior notes, consisting of $2,250,000,000 in aggregate principal amount of its 4.
• $2,500,000,000 — nior notes due 2027 (the "2027 Notes"), $2,500,000,000 in aggregate principal amount of its 4.
• $2,000,000,000 — nior notes due 2029 (the "2029 Notes"), $2,000,000,000 in aggregate principal amount of its 4.
• $3,000,000,000 — nior notes due 2031 (the "2031 Notes"), $3,000,000,000 in aggregate principal amount of its 5.
• $750,000,000 — nior notes due 2034 (the "2034 Notes"), $750,000,000 in aggregate principal amount of its 5.
• $1,500,000,000 — r notes due 2054 (the "2054 Notes") and $1,500,000,000 in aggregate principal amount of its 5.
• $5.0 billion — ssuance of the Notes: (i) to prepay its $5.0 billion 364-day term loan, the proceeds of whic

Filing Documents

• tm246405d5_8k.htm (8-K) — 53KB
• tm246405d5_ex1-1.htm (EX-1.1) — 230KB
• tm246405d5_ex4-2.htm (EX-4.2) — 65KB
• tm246405d5_ex4-3.htm (EX-4.3) — 50KB
• tm246405d5_ex4-4.htm (EX-4.4) — 50KB
• tm246405d5_ex4-5.htm (EX-4.5) — 53KB
• tm246405d5_ex4-6.htm (EX-4.6) — 49KB
• tm246405d5_ex4-7.htm (EX-4.7) — 48KB
• tm246405d5_ex4-8.htm (EX-4.8) — 49KB
• tm246405d5_ex4-9.htm (EX-4.9) — 49KB
• tm246405d5_ex5-1.htm (EX-5.1) — 38KB
• tm246405d5_ex5-1img001.jpg (GRAPHIC) — 3KB
• 0001104659-24-027585.txt ( ) — 1141KB
• abbv-20240222.xsd (EX-101.SCH) — 5KB
• abbv-20240222_def.xml (EX-101.DEF) — 30KB
• abbv-20240222_lab.xml (EX-101.LAB) — 41KB
• abbv-20240222_pre.xml (EX-101.PRE) — 29KB
• tm246405d5_8k_htm.xml (XML) — 14KB

01. Other Events

Item 8.01. Other Events. On February 22, 2024, AbbVie Inc. ("AbbVie") entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, BofA Securities, Inc. and Citigroup Global Markets Inc., acting for themselves and as representatives of the several underwriters named therein (collectively, the "Underwriters"), pursuant to which AbbVie agreed to issue and sell to the Underwriters $15.0 billion aggregate principal amount of its senior notes, consisting of $2,250,000,000 in aggregate principal amount of its 4.800% senior notes due 2027 (the "2027 Notes"), $2,500,000,000 in aggregate principal amount of its 4.800% senior notes due 2029 (the "2029 Notes"), $2,000,000,000 in aggregate principal amount of its 4.950% senior notes due 2031 (the "2031 Notes"), $3,000,000,000 in aggregate principal amount of its 5.050% senior notes due 2034 (the "2034 Notes"), $750,000,000 in aggregate principal amount of its 5.350% senior notes due 2044 (the "2044 Notes"), $3,000,000,000 of its 5.400% senior notes due 2054 (the "2054 Notes") and $1,500,000,000 in aggregate principal amount of its 5.500% senior notes due 2064 (the "2064 Notes," and together with the 2027 Notes, the 2029 Notes, the 2031 Notes, the 2034 Notes and the 2044 Notes and the 2054, the "Notes") in a registered public offering. The Notes were registered under the Securities Act of 1933, as amended (the "Act"), pursuant to AbbVie's registration statement on Form S-3ASR (File No. 333-262908) (the "Registration Statement") dated as of February 22, 2022. On February 26, 2024, AbbVie filed with the Securities and Exchange Commission a prospectus supplement (the "Prospectus Supplement"), containing the final terms of the Notes pursuant to Rule 424(b)(5) of the Act. The Notes were sold pursuant to the Underwriting Agreement and were issued pursuant to the Prospectus Supplement. The Notes are governed by an indenture, dated November 8, 2012 (the "Base Indentu

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibits are provided as part of this Form 8-K: 1.1 Underwriting Agreement, dated February 22, 2024, by and among AbbVie Inc., Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, BofA Securities, Inc. and Citigroup Global Markets Inc. (acting for themselves and as representatives of the several underwriters named therein) 4.1 Indenture, dated November 8, 2012, between AbbVie Inc. and U.S. Bank Trust Company, National Association, as trustee (incorporated by reference to Exhibit 4.1 of Amendment No. 5 to AbbVie's Registration Statement on Form 10 filed November 16, 2012). 4.2 Supplemental Indenture No. 10, dated February 26, 2024, between AbbVie Inc. and U.S. Bank Trust Company, National Association, as trustee. 4.3 Form of 4.800% Note due 2027 (included in Exhibit 4.2 of this Current Report on Form 8-K) 4.4 Form of 4.800 Note due 2029 (included in Exhibit 4.2 of this Current Report on Form 8-K) 4.5 Form of 4.950% Note due 2031 (included in Exhibit 4.2 of this Current Report on Form 8-K) 4.6 Form of 5.050% Note due 2034 (included in Exhibit 4.2 of this Current Report on Form 8-K) 4.7 Form of 5.350% Note due 2044 (included in Exhibit 4.2 of this Current Report on Form 8-K) 4.8 Form of 5.400% Note due 2054 (included in Exhibit 4.2 of this Current Report on Form 8-K) 4.9 Form of 5.500% Note due 2064 (included in Exhibit 4.2 of this Current Report on Form 8-K) 5.1 Opinion of Wachtell, Lipton, Rosen & Katz, dated February 26, 2024, with respect to the Notes. 23.1 Consent of Wachtell, Lipton, Rosen & Katz (included in Exhibit 5.1 of this Current Report on Form 8-K) 104 Cover Page Interactive Data File--the cover page XBRL are embedded within the Inline XBRL document. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authoriz

View Full Filing

View this 8-K filing on SEC EDGAR